Hansa Biopharma AB (publ) (STO: HNSA)
Sweden
· Delayed Price · Currency is SEK 30.60
+0.62 (2.07%)
Nov 20, 2024, 5:29 PM CET
Hansa Biopharma AB Income Statement
Financials in millions SEK. Fiscal year is January - December.
Millions SEK. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 - 2014 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '24 Sep 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2018 - 2014 |
| Revenue | 189.39 | 134.09 | 154.53 | 33.88 | 6.1 | 3.36 | Upgrade
|
| Revenue Growth (YoY) | 65.48% | -13.22% | 356.12% | 455.56% | 81.27% | 0.18% | Upgrade
|
| Cost of Revenue | 88.19 | 63.14 | 38.48 | 15.43 | 1 | 0.87 | Upgrade
|
| Gross Profit | 101.2 | 70.95 | 116.05 | 18.45 | 5.1 | 2.5 | Upgrade
|
| Selling, General & Admin | 355.07 | 450.49 | 337.86 | 327.27 | 202.99 | 167.31 | Upgrade
|
| Research & Development | 375.92 | 411.33 | 346.24 | 230.76 | 227.19 | 192.95 | Upgrade
|
| Other Operating Expenses | -3.34 | -2.38 | 8.06 | - | - | -0.17 | Upgrade
|
| Operating Expenses | 727.64 | 859.45 | 692.17 | 558.03 | 430.18 | 360.09 | Upgrade
|
| Operating Income | -626.45 | -788.5 | -576.12 | -539.58 | -425.08 | -357.6 | Upgrade
|
| Interest Expense | -95.31 | -105.52 | -43.67 | -0.69 | -0.26 | -0.47 | Upgrade
|
| Interest & Investment Income | 28.06 | 28.06 | 8.83 | 0.07 | 0.39 | 0.12 | Upgrade
|
| Currency Exchange Gain (Loss) | 35.14 | 35.14 | 5.95 | -7.4 | 2.27 | -2.09 | Upgrade
|
| Other Non Operating Income (Expenses) | 16.99 | - | -4.97 | -0.53 | 1.78 | 0.45 | Upgrade
|
| EBT Excluding Unusual Items | -641.56 | -830.81 | -609.98 | -548.13 | -420.89 | -359.59 | Upgrade
|
| Pretax Income | -654.36 | -830.81 | -609.98 | -548.13 | -420.89 | -359.59 | Upgrade
|
| Income Tax Expense | 0.42 | 0.91 | 1.16 | 0.15 | -0.04 | 0.42 | Upgrade
|
| Net Income | -654.78 | -831.72 | -611.13 | -548.28 | -420.85 | -360.01 | Upgrade
|
| Net Income to Common | -654.78 | -831.72 | -611.13 | -548.28 | -420.85 | -360.01 | Upgrade
|
| Shares Outstanding (Basic) | 59 | 53 | 45 | 44 | 42 | 40 | Upgrade
|
| Shares Outstanding (Diluted) | 59 | 53 | 45 | 44 | 42 | 40 | Upgrade
|
| Shares Change (YoY) | 15.98% | 16.95% | 1.01% | 5.45% | 5.39% | 4.42% | Upgrade
|
| EPS (Basic) | -11.09 | -15.83 | -13.60 | -12.33 | -9.98 | -9.00 | Upgrade
|
| EPS (Diluted) | -11.09 | -15.83 | -13.60 | -12.33 | -9.98 | -9.00 | Upgrade
|
| Free Cash Flow | -699.74 | -755.94 | -506.06 | -483.57 | -290.57 | -337.47 | Upgrade
|
| Free Cash Flow Per Share | -11.85 | -14.39 | -11.26 | -10.87 | -6.89 | -8.43 | Upgrade
|
| Gross Margin | 53.43% | 52.91% | 75.10% | 54.47% | 83.65% | 74.26% | Upgrade
|
| Operating Margin | -330.77% | -588.02% | -372.83% | -1592.72% | -6970.76% | -10630.05% | Upgrade
|
| Profit Margin | -345.73% | -620.25% | -395.49% | -1618.40% | -6901.49% | -10701.81% | Upgrade
|
| Free Cash Flow Margin | -369.47% | -563.74% | -327.50% | -1427.38% | -4764.97% | -10031.93% | Upgrade
|
| EBITDA | -623.31 | -785.67 | -573.71 | -538.06 | -422.29 | -355.47 | Upgrade
|
| D&A For EBITDA | 3.14 | 2.83 | 2.41 | 1.52 | 2.79 | 2.13 | Upgrade
|
| EBIT | -626.45 | -788.5 | -576.12 | -539.58 | -425.08 | -357.6 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.